<?xml version="1.0" encoding="UTF-8"?>
<ref id="B33-vaccines-08-00174">
 <label>33.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>DiazGranados</surname>
    <given-names>C.A.</given-names>
   </name>
   <name>
    <surname>Langevin</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Bonaparte</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Sridhar</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Machabert</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Dayan</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Forrat</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Savarino</surname>
    <given-names>S.</given-names>
   </name>
  </person-group>
  <article-title>CYD-TDV dengue vaccine performance by baseline immune profile (monotypic/multitypic) in dengue seropositive individuals</article-title>
  <source>Clin. Infect. Dis.</source>
  <year>2020</year>
  <pub-id pub-id-type="doi">10.1093/cid/ciaa304</pub-id>
  <?supplied-pmid 32198515?>
  <pub-id pub-id-type="pmid">32198515</pub-id>
 </element-citation>
</ref>
